Session » (0387–0429) Pediatric Rheumatology – Clinical Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0388

A Scoping Review of Outcomes of Adults With Childhood-Onset Systemic Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0389

An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0395

Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year

10:30AM-12:30PM: Abstract Number: 0387

Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-Sectional Study Using the 2016–2021 National Survey of Children’s Health

10:30AM-12:30PM: Abstract Number: 0392

Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)

10:30AM-12:30PM: Abstract Number: 0422

Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0406

Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0409

Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0404

Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

10:30AM-12:30PM: Abstract Number: 0393

Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0398

Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry

10:30AM-12:30PM: Abstract Number: 0418

Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0399

External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0425

High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease

10:30AM-12:30PM: Abstract Number: 0403

IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial

10:30AM-12:30PM: Abstract Number: 0417

Implementation of a Communication Aid in Juvenile Idiopathic Arthritis Patient Visits, a Quality Improvement Study

10:30AM-12:30PM: Abstract Number: 0408

Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0413

Improving Access to Timely Joint Injections for Pediatric Rheumatology Patients – A Quality Improvement Initiative

10:30AM-12:30PM: Abstract Number: 0410

Improving Outcomes in Patients with Juvenile Idiopathic Arthritis through a Novel Chronic Condition Value-Based Care Program

10:30AM-12:30PM: Abstract Number: 0421

Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center

10:30AM-12:30PM: Abstract Number: 0424

Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India

10:30AM-12:30PM: Abstract Number: 0405

Juvenile Psoriatic Arthritis and Enthesitis-Related Arthritis: 4-Year Results From the JUNIPERA Extension Study

10:30AM-12:30PM: Abstract Number: 0420

Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial

10:30AM-12:30PM: Abstract Number: 0401

Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry

10:30AM-12:30PM: Abstract Number: 0423

Macrophage activation syndrome-associated proteins and enhanced interferon gamma responsiveness characterize the plasma proteome of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in a pre-treatment replication single center cohort

10:30AM-12:30PM: Abstract Number: 0427

Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts

10:30AM-12:30PM: Abstract Number: 0411

Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

10:30AM-12:30PM: Abstract Number: 0416

Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting

10:30AM-12:30PM: Abstract Number: 0397

Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom

10:30AM-12:30PM: Abstract Number: 0414

Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study

10:30AM-12:30PM: Abstract Number: 0394

Predictors of quality of Life in a longitudinal cohort of patients with Uveitis, Juvenile Idiopathic Arthritis, and JIA-associated uveitis

10:30AM-12:30PM: Abstract Number: 0396

Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers

10:30AM-12:30PM: Abstract Number: 0390

Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI

10:30AM-12:30PM: Abstract Number: 0429

Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients

10:30AM-12:30PM: Abstract Number: 0400

Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0402

Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions

10:30AM-12:30PM: Abstract Number: 0412

The Association of Obesity with Juvenile Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 0415

The Impact of Social Vulnerability Index Scores in Pediatric Uveitis

10:30AM-12:30PM: Abstract Number: 0428

The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts

10:30AM-12:30PM: Abstract Number: 0407

The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort

10:30AM-12:30PM: Abstract Number: 0426

Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.

10:30AM-12:30PM: Abstract Number: 0419

Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results

10:30AM-12:30PM: Abstract Number: 0391

Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].